Get the Stockscreener App
154.48
5.90%
9.18
Insmed Inc stock is traded at $154.48, with a volume of 2.91M.
It is up +5.90% in the last 24 hours and up +3.04% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$145.30
Open:
$150.98
24h Volume:
2.91M
Relative Volume:
1.21
Market Cap:
$33.29B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-24.13
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
+6.87%
1M Performance:
+3.04%
6M Performance:
+6.85%
1Y Performance:
+97.30%
1-Day Range:
$149.35
$155.20
1-Week Range:
$137.19
$155.20
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
154.43 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
441.45 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.50 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
701.92 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.47 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data - Investing.com
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
SG Americas Securities LLC Buys 49,356 Shares of Insmed, Inc. $INSM - MarketBeat
Positive Phase 3b study update sees Insmed stock drop 1.56% - Traders Union
Nordea Investment Management AB Makes New Investment in Insmed, Inc. $INSM - MarketBeat
Vanguard disaggregates holdings; Insmed (NASDAQ: INSM) shows 0 shares - Stock Titan
Assenagon Asset Management S.A. Sells 22,419 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Stock: HC Wainwright & Co. Raises Price Target to $245 | IN - gurufocus.com
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Insmed stock price target on ARIKAYCE data - Investing.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed shares rise on positive results from ARIKAYCE Phase 3b study - MSN
Insmed jumps 6.6% as attention returns to upcoming ENCORE readout for ARIKAYCE - quiverquant.com
Insmed CEO reveals Japan patient population exceeds US market for lung disease - AOL.com
Insmed (NASDAQ:INSM) Price Target Raised to $206.00 at Mizuho - MarketBeat
INSM Stock: Mizuho Raises Price Target Amid Stable Outlook | INS - gurufocus.com
Insmed (NASDAQ:INSM) Price Target Upgrades Drive Nasdaq Index Focus - Kalkine Media
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $177 - Moomoo
INSM: Leerink Partners Raises Price Target, Maintains Outperform Rating | INSM Stock News - GuruFocus
INSM: Wells Fargo Raises Price Target to $177, Reaffirms Overwei - GuruFocus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
B of A Securities Maintains Buy Rating for INSM, Raises Price Ta - GuruFocus
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
Apogee Therapeutics, Insmed, Sunoco - TradingView
Insmed (NASDAQ:INSM) Price Target Raised to $215.00 at Leerink Partners - MarketBeat
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $143.69 to $243 - Moomoo
INSM shares rise following Arikayce's successful outcome in label expansion trial - Bitget
Stifel Nicolaus Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
INSM: Stifel Raises Price Target, Continues Buy Rating | INSM St - gurufocus.com
Mizuho raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Mizuho raises Insmed stock price target on positive trial data - Investing.com
Mizuho Securities Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $206 - Moomoo
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Bank of America Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success - Yahoo Finance
Stifel raises Insmed stock price target on positive trial data - Investing.com
Mizuho Lifts Price Target on Insmed to $206 From $204, Keeps Outperform Rating - marketscreener.com
Stocks Flashing Renewed Technical Strength: Insmed - Investor's Business Daily
Insmed reports positive Phase 3b trial results for MAC lung disease drug - Investing.com Australia
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data - Yahoo Finance
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Insmed CEO on its Arikayce drug after shares surge on trial results - MSN
Insmed Shares Climb on Positive Results for Arikayce - marketscreener.com
Market movers: Palantir Technologies, Insmed, Synopsys… - Proactive financial news
Insmed Announces Positive Phase 3b ENCORE Results for ARIKAYCE in MAC Lung Disease, Plans FDA Supplemental NDA Filing in 2026 - Minichart
BofA raises Insmed stock price target on positive trial data By Investing.com - Investing.com Canada
Insmed (INSM) Achieves Milestone with Positive Phase 3 ENCORE Tr - gurufocus.com
Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - Benzinga
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains - MarketBeat
Insmed (INSM): ENCORE Phase 3 Success Expands MAC Lung Disease Opportunity and Underscores Arikayce Upside - TipRanks
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):